Immunotherapy May Address ‘Huge Need’ in Advanced Endometrial Cancer
March 22nd 2024Amanda Duck, PA-C, RD, held a discussion during a Community Case Forum on the progress made in using immunotherapy to treat patients with advanced endometrial cancer and the creativity sometimes needed to address adverse events.
Tracking Symptoms, Physical Activity With Wearable Technology in Oncology Nursing
March 4th 2024Even though wearable technology can track symptoms and physical activity, among other information, in patients with cancer, more research is needed to determine how it all can benefit the management of these patients by oncology nurses.
FDA Approves Amivantamab Plus Chemo Combo for Advanced NSCLC With EGFR Exon 20 Insertion Mutations
March 1st 2024Amivantamab was approved by the FDA as first-line treatment of patients with locally advanced or metastatic NSCLC with EGFR exon 20 insertion mutations or as therapy for those whose disease progressed on or after platinum-based chemotherapy.
Osimertinib Receives Approval From FDA for EGFR-Mutated Locally Advanced or Metastatic NSCLC
February 16th 2024The FDA approved osimertinib for use with platinum-based chemotherapy to treat patients with locally advanced or metastatic non-small cell lung cancer that harbor EGFR exon 19 deletions or exon 21 L858R mutations.
Darolutamide Plus ADT May Lower Hospitalization Rates, Slightly Prolong Stays in mHSPC
January 25th 2024Darolutamide plus androgen deprivation therapy and docetaxel in patients with metastatic hormone-sensitive prostate cancer may lower hospitalization rates but marginally longer lengths of stay vs treatment with placebo, androgen deprivation therapy, and docetaxel.
Informing Patients With Cancer on Available Resources Can Address Financial Toxicity
January 15th 2024Speaking with patients with cancer about financial toxicity, including available resources to help them pay for treatment and other necessities, can become a collaborative effort within an institution.